Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma.

Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, Laing S, Kruspig B, Upstill-Goddard R, Shaw R, Neidler S, Rink C, Karim SA, Gyuraszova K, Nixon C, Clark W, Biankin AV, Carlin LM, Coffelt SB, Sansom OJ, Morton JP, Murphy DJ.

Cancer Discov. 2020 Mar 21. pii: CD-19-0620. doi: 10.1158/2159-8290.CD-19-0620. [Epub ahead of print]

2.

MCL1 is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice.

Healy ME, Boege Y, Hodder MC, Böhm F, Malehmir M, Scherr AL, Jetzer J, Chan LK, Parrotta R, Jacob K, Clerbaux LA, Kreutzer S, Campbell A, Gilchrist E, Gilroy K, Rodewald AK, Honcharova-Biletska H, Schimmer R, Vélez K, Büeler S, Cammareri P, Kalna G, Wenning AS, McCoy KD, Gomez de Agüero M, Schulze-Bergkamen H, Klose C, Unger K, Macpherson AJ, Moor AE, Köhler B, Sansom OJ, Heikenwalder M, Weber A.

Gastroenterology. 2020 Mar 13. pii: S0016-5085(20)30338-3. doi: 10.1053/j.gastro.2020.03.017. [Epub ahead of print]

3.

RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome.

Rooney N, Mason SM, McDonald L, Däbritz JHM, Campbell KJ, Hedley A, Howard S, Athineos D, Nixon C, Clark W, Leach JDG, Sansom OJ, Edwards J, Cameron ER, Blyth K.

Cancer Res. 2020 Mar 10. pii: canres.3870.2019. doi: 10.1158/0008-5472.CAN-19-3870. [Epub ahead of print]

4.

Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition.

Michalopoulou E, Auciello FR, Bulusu V, Strachan D, Campbell AD, Tait-Mulder J, Karim SA, Morton JP, Sansom OJ, Kamphorst JJ.

Cell Rep. 2020 Feb 25;30(8):2729-2742.e4. doi: 10.1016/j.celrep.2020.01.080.

5.

Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D.

Kennedy SA, Jarboui MA, Srihari S, Raso C, Bryan K, Dernayka L, Charitou T, Bernal-Llinares M, Herrera-Montavez C, Krstic A, Matallanas D, Kotlyar M, Jurisica I, Curak J, Wong V, Stagljar I, LeBihan T, Imrie L, Pillai P, Lynn MA, Fasterius E, Al-Khalili Szigyarto C, Breen J, Kiel C, Serrano L, Rauch N, Rukhlenko O, Kholodenko BN, Iglesias-Martinez LF, Ryan CJ, Pilkington R, Cammareri P, Sansom O, Shave S, Auer M, Horn N, Klose F, Ueffing M, Boldt K, Lynn DJ, Kolch W.

Nat Commun. 2020 Jan 24;11(1):499. doi: 10.1038/s41467-019-14224-9.

6.

Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors.

Wilson DH, Jarman EJ, Mellin RP, Wilson ML, Waddell SH, Tsokkou P, Younger NT, Raven A, Bhalla SR, Noll ATR, Olde Damink SW, Schaap FG, Chen P, Bates DO, Banales JM, Dean CH, Henderson DJ, Sansom OJ, Kendall TJ, Boulter L.

Nat Commun. 2020 Jan 23;11(1):445. doi: 10.1038/s41467-020-14283-3.

7.

Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.

Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P, Balkwill FR.

Cell Rep. 2020 Jan 14;30(2):525-540.e7. doi: 10.1016/j.celrep.2019.12.034.

8.

Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.

Kaymak I, Maier CR, Schmitz W, Campbell AD, Dankworth B, Ade CP, Walz S, Paauwe M, Kalogirou C, Marouf H, Rosenfeldt MT, Gay DM, McGregor GH, Sansom OJ, Schulze A.

Cancer Res. 2020 Jan 15;80(2):189-203. doi: 10.1158/0008-5472.CAN-19-0650. Epub 2019 Nov 19.

9.

mTORC1 activity is essential for erythropoiesis and B cell lineage commitment.

Malik N, Dunn KM, Cassels J, Hay J, Estell C, Sansom OJ, Michie AM.

Sci Rep. 2019 Nov 15;9(1):16917. doi: 10.1038/s41598-019-53141-1.

10.

Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.

Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, Mrowinska A, Loveridge CJ, Rushworth LK, Edwards J, Ntala C, Nixon C, Hedley A, Mackay G, Tardito S, Sansom OJ, Leung HY.

Cancer Res. 2020 Feb 1;80(3):576-590. doi: 10.1158/0008-5472.CAN-19-1684. Epub 2019 Nov 12.

11.

A MYC-GCN2-eIF2α negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer.

Schmidt S, Gay D, Uthe FW, Denk S, Paauwe M, Matthes N, Diefenbacher ME, Bryson S, Warrander FC, Erhard F, Ade CP, Baluapuri A, Walz S, Jackstadt R, Ford C, Vlachogiannis G, Valeri N, Otto C, Schülein-Völk C, Maurus K, Schmitz W, Knight JRP, Wolf E, Strathdee D, Schulze A, Germer CT, Rosenwald A, Sansom OJ, Eilers M, Wiegering A.

Nat Cell Biol. 2019 Nov;21(11):1413-1424. doi: 10.1038/s41556-019-0408-0. Epub 2019 Nov 4.

PMID:
31685988
12.

Targeting the Metabolic Response to Statin-Mediated Oxidative Stress Produces a Synergistic Antitumor Response.

McGregor GH, Campbell AD, Fey SK, Tumanov S, Sumpton D, Blanco GR, Mackay G, Nixon C, Vazquez A, Sansom OJ, Kamphorst JJ.

Cancer Res. 2020 Jan 15;80(2):175-188. doi: 10.1158/0008-5472.CAN-19-0644. Epub 2019 Sep 27.

13.

Correction: Lkb1 Deficiency Alters Goblet and Paneth Cell Differentiation in the Small Intestine.

Shorning BY, Zabkiewicz J, McCarthy A, Pearson HB, Winton DJ, Sansom OJ, Ashworth A, Clarke AR.

PLoS One. 2019 Sep 19;14(9):e0223041. doi: 10.1371/journal.pone.0223041. eCollection 2019.

14.

Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis.

Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, Horgan PG, Nixon C, Nourse C, Gunzer M, Clark W, Hedley A, Yilmaz OH, Rashid M, Bailey P, Biankin AV, Campbell AD, Adams DJ, Barry ST, Steele CW, Medema JP, Sansom OJ.

Cancer Cell. 2019 Sep 16;36(3):319-336.e7. doi: 10.1016/j.ccell.2019.08.003.

15.

Pancreatic Cancer: From Genome Discovery to PRECISION-Panc.

Dreyer SB, Jamieson NB, Morton JP, Sansom OJ, Biankin AV, Chang DK.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):5-8. doi: 10.1016/j.clon.2019.08.007. Epub 2019 Sep 12. No abstract available.

PMID:
31522943
16.

Report of the 113th Annual Meeting of the Association of Physicians of Great Britain and Ireland.

Dominiczak DA, Samani N, Sudlow C, Sansom O, Davies DS.

QJM. 2019 Sep 1;112(9):733-742. doi: 10.1093/qjmed/hcz176. No abstract available.

PMID:
31505684
17.

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan.

Vennin C, Mélénec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W; Australian Pancreatic Genome Initiative (APGI), Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P.

Nat Commun. 2019 Aug 12;10(1):3637. doi: 10.1038/s41467-019-10968-6.

18.

The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.

Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF.

J Pathol. 2019 Nov;249(3):332-342. doi: 10.1002/path.5320. Epub 2019 Jul 30.

19.

Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis.

Rohwer N, Jumpertz S, Erdem M, Egners A, Warzecha KT, Fragoulis A, Kühl AA, Kramann R, Neuss S, Rudolph I, Endermann T, Zasada C, Apostolova I, Gerling M, Kempa S, Hughes R, Lewis CE, Brenner W, Malinowski MB, Stockmann M, Schomburg L, Faller W, Sansom OJ, Tacke F, Morkel M, Cramer T.

Oncogene. 2019 Jul;38(28):5670-5685. doi: 10.1038/s41388-019-0816-4. Epub 2019 May 1.

20.

Author Correction: Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.

Gay DM, Ridgway RA, Müller M, Hodder MC, Hedley A, Clark W, Leach JD, Jackstadt R, Nixon C, Huels DJ, Campbell AD, Bird TG, Sansom OJ.

Nat Commun. 2019 Mar 26;10(1):1453. doi: 10.1038/s41467-019-09465-7.

21.

Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas.

Liko D, Mitchell L, Campbell KJ, Ridgway RA, Jones C, Dudek K, King A, Bryson S, Stevenson D, Blyth K, Strathdee D, Morton JP, Bird TG, Knight JRP, Willis AE, Sansom OJ.

Cell Death Differ. 2019 Dec;26(12):2535-2550. doi: 10.1038/s41418-019-0316-7. Epub 2019 Mar 11.

22.

RAL GTPases Drive Intestinal Stem Cell Function and Regeneration through Internalization of WNT Signalosomes.

Johansson J, Naszai M, Hodder MC, Pickering KA, Miller BW, Ridgway RA, Yu Y, Peschard P, Brachmann S, Campbell AD, Cordero JB, Sansom OJ.

Cell Stem Cell. 2019 Apr 4;24(4):592-607.e7. doi: 10.1016/j.stem.2019.02.002. Epub 2019 Mar 7.

23.

Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.

Gay DM, Ridgway RA, Müller M, Hodder MC, Hedley A, Clark W, Leach JD, Jackstadt R, Nixon C, Huels DJ, Campbell AD, Bird TG, Sansom OJ.

Nat Commun. 2019 Feb 13;10(1):723. doi: 10.1038/s41467-019-08586-3. Erratum in: Nat Commun. 2019 Mar 26;10(1):1453.

24.

Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling.

Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S.

Sci Signal. 2019 Feb 5;12(567). pii: eaan8247. doi: 10.1126/scisignal.aan8247.

25.

A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, Schneider R, Sansom O, Wienke D, Ashworth A, Lord CJ.

Sci Rep. 2019 Jan 17;9(1):201. doi: 10.1038/s41598-018-36447-4.

26.

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.

Cosimo E, Tarafdar A, Moles MW, Holroyd AK, Malik N, Catherwood MA, Hay J, Dunn KM, Macdonald AM, Guichard SM, O'Rourke D, Leach MT, Sansom OJ, Cosulich SC, McCaig AM, Michie AM.

Clin Cancer Res. 2019 Mar 1;25(5):1574-1587. doi: 10.1158/1078-0432.CCR-18-2036. Epub 2018 Dec 17.

27.

Correction for Muncan et al., "Rapid Loss of Intestinal Crypts upon Conditional Deletion of the Wnt/Tcf-4 Target Gene c-Myc".

Muncan V, Sansom OJ, Tertoolen L, Phesse TJ, Begthel H, Sancho E, Cole AM, Gregorieff A, Moreno de Alboran I, Clevers H, Clarke AR.

Mol Cell Biol. 2018 Nov 28;38(24). pii: e00482-18. doi: 10.1128/MCB.00482-18. Print 2018 Dec 15. No abstract available.

28.

Mannose impairs tumour growth and enhances chemotherapy.

Gonzalez PS, O'Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, Roseweir A, Gay DM, Mackay G, Malviya G, Kania E, Ritchie S, Baudot AD, Zunino B, Mrowinska A, Nixon C, Ennis D, Hoyle A, Millan D, McNeish IA, Sansom OJ, Edwards J, Ryan KM.

Nature. 2018 Nov;563(7733):719-723. doi: 10.1038/s41586-018-0729-3. Epub 2018 Nov 21.

29.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
30.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.

31.

Microenvironmental cues in cancer stemness.

Flanagan DJ, Hodder MC, Sansom OJ.

Nat Cell Biol. 2018 Oct;20(10):1102-1104. doi: 10.1038/s41556-018-0210-4. No abstract available.

PMID:
30258126
32.

The role of mTOR-mediated signals during haemopoiesis and lineage commitment.

Malik N, Sansom OJ, Michie AM.

Biochem Soc Trans. 2018 Oct 19;46(5):1313-1324. doi: 10.1042/BST20180141. Epub 2018 Aug 28. Review.

33.

Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis.

Greenhough A, Bagley C, Heesom KJ, Gurevich DB, Gay D, Bond M, Collard TJ, Paraskeva C, Martin P, Sansom OJ, Malik K, Williams AC.

EMBO Mol Med. 2018 Nov;10(11). pii: e8699. doi: 10.15252/emmm.201708699.

34.

TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence.

Bird TG, Müller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, Lu WY, Jamieson T, Govaere O, Campbell AD, Ferreira-Gonzalez S, Cole AM, Hay T, Simpson KJ, Clark W, Hedley A, Clarke M, Gentaz P, Nixon C, Bryce S, Kiourtis C, Sprangers J, Nibbs RJB, Van Rooijen N, Bartholin L, McGreal SR, Apte U, Barry ST, Iredale JP, Clarke AR, Serrano M, Roskams TA, Sansom OJ, Forbes SJ.

Sci Transl Med. 2018 Aug 15;10(454). pii: eaan1230. doi: 10.1126/scitranslmed.aan1230.

35.

Systems level expression correlation of Ras GTPase regulators.

Besray Unal E, Kiel C, Benisty H, Campbell A, Pickering K, Blüthgen N, Sansom OJ, Serrano L.

Cell Commun Signal. 2018 Aug 15;16(1):46. doi: 10.1186/s12964-018-0256-8.

36.

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M.

Oncogene. 2018 Dec;37(49):6368-6382. doi: 10.1038/s41388-018-0390-1. Epub 2018 Jul 30.

PMID:
30061636
37.

FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, Sjödahl G, Salmond JM, Sansom OJ, Iwata T.

J Pathol. 2018 Nov;246(3):331-343. doi: 10.1002/path.5143. Epub 2018 Sep 19.

38.

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.

Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP, Timpson P.

Cell Rep. 2018 Jun 12;23(11):3312-3326. doi: 10.1016/j.celrep.2018.05.038.

39.

Intestinal Stem Cell Dynamics: A Story of Mice and Humans.

Hodder MC, Flanagan DJ, Sansom OJ.

Cell Stem Cell. 2018 Jun 1;22(6):785-787. doi: 10.1016/j.stem.2018.05.005.

40.

MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus.

Godfrey JD, Morton JP, Wilczynska A, Sansom OJ, Bushell MD.

Cell Death Dis. 2018 May 29;9(6):644. doi: 10.1038/s41419-018-0628-4.

41.

STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap.

Woroniuk A, Porter A, White G, Newman DT, Diamantopoulou Z, Waring T, Rooney C, Strathdee D, Marston DJ, Hahn KM, Sansom OJ, Zech T, Malliri A.

Nat Commun. 2018 May 29;9(1):2124. doi: 10.1038/s41467-018-04404-4.

42.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

43.

Loss of N-WASP drives early progression in an Apc model of intestinal tumourigenesis.

Morris HT, Fort L, Spence HJ, Patel R, Vincent DF, Park JH, Snapper SB, Carey FA, Sansom OJ, Machesky LM.

J Pathol. 2018 Jul;245(3):337-348. doi: 10.1002/path.5086. Epub 2018 May 28.

44.

Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation.

May S, Owen H, Phesse TJ, Greenow KR, Jones GR, Blackwood A, Cook PC, Towers C, Gallimore AM, Williams GT, Stürzl M, Britzen-Laurent N, Sansom OJ, MacDonald AS, Bird AP, Clarke AR, Parry L.

J Pathol. 2018 Jul;245(3):270-282. doi: 10.1002/path.5074. Epub 2018 May 16.

45.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Jun;8(6):764-779. doi: 10.1158/2159-8290.CD-17-0867. Epub 2018 Mar 26.

46.

Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells.

Huels DJ, Bruens L, Hodder MC, Cammareri P, Campbell AD, Ridgway RA, Gay DM, Solar-Abboud M, Faller WJ, Nixon C, Zeiger LB, McLaughlin ME, Morrissey E, Winton DJ, Snippert HJ, van Rheenen J, Sansom OJ.

Nat Commun. 2018 Mar 19;9(1):1132. doi: 10.1038/s41467-018-03426-2.

47.

Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

Patel R, Fleming J, Mui E, Loveridge C, Repiscak P, Blomme A, Harle V, Salji M, Ahmad I, Teo K, Hamdy FC, Hedley A, van den Broek N, Mackay G, Edwards J, Sansom OJ, Leung HY.

EMBO Mol Med. 2018 Apr;10(4). pii: e8347. doi: 10.15252/emmm.201708347.

48.

Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress.

Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M, Esumi H, Murray GI, Sansom OJ, Zanivan SR, Murphy DJ.

Cancer Discov. 2018 May;8(5):632-647. doi: 10.1158/2159-8290.CD-17-0533. Epub 2018 Mar 2.

49.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernández-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S, Watkins D, Fotiadis N, Bali M, Darvish-Damavandi M, Lote H, Eltahir Z, Smyth EC, Begum R, Clarke PA, Hahne JC, Dowsett M, de Bono J, Workman P, Sadanandam A, Fassan M, Sansom OJ, Eccles S, Starling N, Braconi C, Sottoriva A, Robinson SP, Cunningham D, Valeri N.

Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774.

50.

Spatiotemporal regulation of liver development by the Wnt/β-catenin pathway.

Burke ZD, Reed KR, Yeh SW, Meniel V, Sansom OJ, Clarke AR, Tosh D.

Sci Rep. 2018 Feb 9;8(1):2735. doi: 10.1038/s41598-018-20888-y.

Supplemental Content

Loading ...
Support Center